PDCD1LG2 and neoplasm: The biomarkers used in cancer immunotherapy include PD-L1 and PD-L2 expression levels, microsatellite instability (MSI) status, neoantigen presence, and Tumor Mutational Load or Tumor Mutational Burden (TMB) (Shu et al., 2020).